Global Hantavirus Diagnostics Market -2024-2031

Global Hantavirus Diagnostics Market -2024-2031


Global Hantavirus Diagnostics Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Hantaviruses are a family of viruses spread mainly by rodents and can cause varied disease syndromes in people worldwide. Infection with any hantavirus can produce hantavirus disease in people. Each hantavirus serotype has a specific rodent host species and is spread to people via an aerosolized virus that is shed in urine, faeces, and saliva, and less frequently by a bite from an infected host. The most important hantavirus in the United States that can cause HPS is the Sin Nombre virus, spread by the deer mouse.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of hantavirus

In humans, Hantaviruses can cause serious fatal diseases such as hemorrhagic fever renal syndrome (HFRS) in Asia, HFRS and nephropathia epidemica (NE) in Europe and Hantavirus cardiopulmonary syndrome (HCPS) in North and South Americas. In recent years, almost 200,000 people around the world have been affected by Hantaviruses annually, with a case fatality of 1–15% for HFRS, 0.1–1% for NE and up to 40–60% for HCPS.

Two significant outbreaks were documented in the last century which brought the Hantavirus disease to worldwide attention. More than 3,000 United Nations forces contracted the HFRS during the Korean War (1950–1953), which was the first time it happened and the second was the outbreak of HCPS in 1993 in the Four Corners area of the United States.

Furthermore, global hantavirus diagnostics are also driven by various other factors like a rise in the advancements in the therapeutics, novel kit launches by key players and others helping the market to grow during the forecast period.

Complications associated with the disease

Early symptoms include fatigue, fever and muscle aches, especially in the large muscle groups—thighs, hips, back, and sometimes shoulders. These symptoms are universal. There may also be headaches, dizziness, chills, and abdominal problems, such as nausea, vomiting, diarrhea, and abdominal pain.

For more details on this report – Request for Sample

Segment Analysis

The global hantavirus diagnostics market is segmented based on disease type, test technology, end-user and region.

The hantavirus pulmonary syndrome (HPS) from the disease type segment accounted for approximately 51.7 % of the Hantavirus Diagnostics market share

The hantavirus pulmonary syndrome (HPS) from the disease type segment accounted for approximately 51.7%. Hantavirus pulmonary syndrome (HPS) is a rare but potentially life-threatening viral illness transmitted to humans from the infected urine, droppings or saliva of certain species of mice and rats. Most cases of HPS in the United States have occurred in the Southwest among people who are exposed to these rodents at their work or home.

For instance, in February 2024, a study in Gyeonggi Province, South Korea, led by Prof. Jin-Won Song, focused on understanding the genomic diversity of Hantaan orthohantavirus (HTNV) and its prevalence, viral loads, and genetic variations. The study used Flongle sequencing, an innovative, cost-efficient, and rapid method, for detecting HTNV genomes.

Hence, the researchers developed a rapid, sensitive on-site diagnostic using a nanopore-based Flongle chip, costing around $100, enabling whole-genome sequencing of HTNV within 3 hours.

Geographical Analysis

North America is estimated to hold about 39.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like rise in the prevalence of hantavirus in the region, collaboration and partnerships, healthcare infrastructure and others that help the region to have the highest market share during the forecast period.

For instance, according to the IDCM factsheet, it is estimated that 100,000 cases of hantavirus occur worldwide each year. HPS is diagnosed sporadically in the United States with cases often occurring in clusters. The largest outbreak occurred in 1993 in the Four Corners area of the Southwest.

Covid 19 Impact Analysis

The COVID-19 pandemic has affected public health investigation and response activities for other illnesses; COVID-19 has particularly challenged the diagnosis of respiratory illnesses because of similar clinical manifestations. Hantavirus pulmonary syndrome is a rare disease transmitted predominantly by infected rodents shedding the virus through saliva, urine, and feces.

Market Segmentation

By Disease Type
• Hantavirus Pulmonary Syndrome (HPS)
• Hemorrhagic Fever with Renal Syndrome (HFRS)

By Test Technology
• Serological Assays
• Immunohistochemistry/Immunofluorescence Tests (IHC/IF)
• Reverse Transcriptase PCR (RT-PCR)
• Others

By End-User
• Hospitals & Clinics
• Clinical Diagnostic Labs
• Research Institutions
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Quest Diagnostics Inc., Express Biotech International Inc., LifeSpan BioSciences Inc., Tecan Group Ltd, Aviva Systems Biology LLC, Atlona Diagnostics, Creative Diagnostics, Progen, DRG Diagnostics GmbH and among others.

Why Purchase the Report?
• To visualize the global hantavirus diagnostics market segmentation based on disease type, test technology, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of the hantavirus diagnostics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hantavirus diagnostics market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies


1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Test Technology
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of hantavirus
4.1.1.2. Rise in advancements of diagnostic kits
4.1.2. Restraints
4.1.2.1. Complications associated with the disease
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Hantavirus Pulmonary Syndrome (HPS)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hemorrhagic Fever with Renal Syndrome (HFRS)
8. By Test Technology
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Technology
8.1.2. Market Attractiveness Index, By Test Technology
8.2. Serological Assays*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Immunohistochemistry/Immunofluorescence Tests (IHC/IF)
8.4. Reverse Transcriptase PCR (RT-PCR)
8.5. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals & Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical Diagnostic Labs
9.4. Research Institutions
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Quest Diagnostics Inc*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Express Biotech International Inc
12.3. LifeSpan BioSciences Inc
12.4. Tecan Group Ltd
12.5. Aviva Systems Biology LLC
12.6. Atlona Diagnostics
12.7. Creative Diagnostics
12.8. Progen
12.9. DRG Diagnostics GmbH
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings